Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

84535 reported adverse events

Drugs of this class: LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE ABACAVIR AND LAMIVUDINE EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE ZIDOVUDINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE DIDANOSINE EMTRICITABINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

#	Side effect	Count
0	BONE DENSITY DECREASED	7656
1	PAIN	4870
2	CHRONIC KIDNEY DISEASE	4609
3	ANXIETY	4240
4	EMOTIONAL DISTRESS	4167
5	RENAL FAILURE	4138
6	FOETAL EXPOSURE DURING PREGNANCY	4063
7	TOOTH LOSS	4030
8	ANHEDONIA	3497
9	OSTEONECROSIS	3183

See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	CSF HIV ESCAPE SYNDROME	83	0.9222
1	PINEALOBLASTOMA	65	0.8553
2	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA	84	0.8400
3	BLOOD HIV RNA INCREASED	618	0.7601
4	IMMUNE RECONSTITUTION SYNDROME	937	0.7241
5	HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION	129	0.6789
6	VIRAL MUTATION IDENTIFIED	1280	0.6390
7	ACUTE HIV INFECTION	99	0.6149
8	MITOCHONDRIAL TOXICITY	327	0.5788
9	LIPODYSTROPHY ACQUIRED	814	0.5511

See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]